Shennon Biotechnologies Raises $12 Million, Unveils T-Cell Oncology Pipeline
The company has raised $25 million to date and plans within two years to advance a development candidate toward an IND filing and Phase 1 clinical development.

Key Points
- Shennon Biotechnologies raised $12 million and appointed Cyril Konto, M.D., as CEO to advance its precision immunotherapy pipeline toward the clinic.
- The company unveiled three oncology programs: SBT-121 for small cell lung cancer, SBT-201 for ovarian cancer, and SBT-425 for hepatocellular carcinoma.
- The financing brings total funding to $25 million and will support an integrated platform spanning target discovery, functional screening, binder optimization, and safety assessment.
Shennon Biotechnologies, a biotechnology company developing precision immunotherapies for cancer, has raised $12 million and appointed oncology drug development veteran Cyril Konto, M.D., as Chief Executive Officer. The San Francisco-based company also unveiled its first three oncology programs, T-cell engager candidates targeting small cell lung cancer, ovarian cancer, and hepatocellular carcinoma.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
The financing came from Future Ventures, NextGen Venture Partners, Samos Investments, Atypical Ventures, and Saras Capital, with continued support from existing investors DCVC, Foundation Capital, and AV8 Ventures. The company has raised $25 million to date.
Founder and current CEO Li Sun, Ph.D., will transition to President and Chief Technology Officer, continuing to lead the company’s scientific strategy, technology development, and pipeline innovation.
Integrated Platform and Proprietary Datasets
The financing will support continued development of ShennonBio’s integrated technology platform and its emerging oncology pipeline. Since its founding in 2021, the company has built a technology engine spanning target discovery, ultra-high-throughput functional screening, computational binder prediction and optimization, and AI-enabled safety assessment. It has also established approximately 6,000 square feet of laboratory space in San Francisco near UCSF Mission Bay and assembled proprietary datasets with fresh tumor samples through partnerships with hospitals and academic institutions.
ShennonBio is developing both antibody-based T-cell engagers (Ab-TCEs), which can address targets expressed on the surface of tumor cells, and TCR-based T-cell engagers (TCR-TCEs), which can potentially access intracellular cancer targets presented through HLA.
The platform combines four proprietary capabilities: PINTRA, which uses proprietary human tumor datasets and computational approaches to identify differentiated surface and intracellular therapeutic targets; TCELERATOR, an ultra-high-throughput functional screening platform capable of evaluating more than 10 million single-cell interactions concurrently; AFFINIS, a computational platform for predicting, designing, and optimizing antibody binders and TCRs; and SERIS, an AI-enabled safety platform designed to identify potential off-target cross-reactivity earlier in therapeutic development.
The company has assembled data encompassing more than 10,000 tumor samples, more than 11 million single cells, and a substantial collection of TCR sequences. ShennonBio continues to expand these datasets through relationships involving more than 15 institutions across multiple cancer types and other diseases.
“ShennonBio was founded to address fundamental challenges that have limited the development of precision immunotherapies, from identifying differentiated targets and highly functional therapeutic binders to predicting potential safety risks before candidates reach the clinic,” said Li Sun, Ph.D., Founder, President and Chief Technology Officer. “We have built an integrated technology platform, generated proprietary human datasets and begun translating those capabilities into a pipeline of precision immunotherapies. With $25 million raised to date, and Cyril joining as CEO, we are entering an important new stage for ShennonBio as we advance our first TCE programs toward the clinic.”
Initial Oncology Pipeline
SBT-121 is a dual-targeting trispecific Ab-TCE being developed for small cell lung cancer. SBT-201 is an Ab-TCE being developed for ovarian cancer. SBT-425 is a TCR-TCE being developed for hepatocellular carcinoma.
Dr. Konto brings more than 20 years of experience in oncology drug development, company building, and strategic transactions. Most recently, he served as President and CEO of Ichnos Glenmark Innovation, where he led a strategic and operational transformation, focused the portfolio on oncology, and built the multispecifics franchise. During his tenure, the company completed three external partnerships, including an agreement with AbbVie for a Phase 1 trispecific T-cell engager that included $700 million upfront and up to $1.9 billion in total potential value plus royalties. He previously held senior oncology development leadership roles at Allogene Therapeutics, Pfizer, and Bristol Myers Squibb.
“ShennonBio has spent the last several years building a differentiated foundation spanning proprietary human data, target discovery, functional screening, therapeutic design and safety prediction,” said Dr. Konto. “What attracted me to the Company is the opportunity to translate those capabilities into a new generation of precision immunotherapies. I look forward to working closely with Li and the team to advance our pipeline toward the clinic, establish strategic partnerships and build ShennonBio for its next stage of growth.”
Over the next two years, ShennonBio plans to advance a development candidate toward an IND filing and Phase 1 clinical development, pursue licensing opportunities for selected therapeutic programs, and explore partnerships around its platform capabilities, including binder prediction and generation, clinical toxicity prediction, and its proprietary datasets.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
